Favipiravir
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
- Favipiravir
- Pharmacist Assessment Report
- Favipiravir: From Influenza to Acquired Hemophagocytic Lymphohistiocytosis Associated with Malignant Disease
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Favipiravir: From Influenza to Acquired Hemophagocytic Lymphohistiocytosis Associated with Malignant Disease
One-Sentence Summary
Favipiravir is an antiviral originally used to treat influenza. The TxGNN model predicts it may be effective for acquired hemophagocytic lymphohistiocytosis associated with malignant disease, but no clinical trials and no publications currently support this prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Influenza |
| Predicted New Indication | Acquired hemophagocytic lymphohistiocytosis associated with malignant disease |
| TxGNN Prediction Score | 0.9941 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on general knowledge, favipiravir is a viral RNA-dependent RNA polymerase inhibitor, and its efficacy in influenza is established.
The predicted new indication is a different kind of disease. Malignancy-associated hemophagocytic lymphohistiocytosis (HLH) is driven by immune dysregulation and cytokine storm, not by a viral target. No plausible direct mechanistic link is evident, and the high score is a model output only.
A related prediction is worth noting as a research question. For hemophagocytic syndrome associated with an infection (same score, 0.9941), an indirect link is plausible: RNA viruses can trigger HLH, and treating the trigger virus might reduce the downstream hyperinflammation. The two papers retrieved for that prediction concern severe fever with thrombocytopenia syndrome and Heartland virus disease. They do not test favipiravir in HLH. That prediction is rated L4 with a “Research Question” status.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for the top-ranked prediction.
For reference, the two papers found for the second-ranked prediction (infection-associated hemophagocytic syndrome) are background reviews only:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 30098914 | 2018 | Review | Journal of Infection and Chemotherapy | Pathophysiology of severe fever with thrombocytopenia syndrome (a tick-borne viral hemorrhagic fever) and development of specific antiviral therapy |
| 38399689 | 2024 | Review | Microorganisms | Review of Heartland virus disease, a tick-borne infection with fever, leukopenia and thrombocytopenia |
India Market Information
Showing 5 of 20 valid single-ingredient registrations. Approved indication text was not available for these products.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 90506 | Favivent 400mg Tablet | Strip of 10 tablets | Not available |
| 89221 | Favtris 200 Tablet | Strip of 10 tablets | Not available |
| 88151 | Fabixa 800mg Tablet | Strip of 10 tablets | Not available |
| 87492 | Favenza 800 Tablet | Strip of 10 tablets | Not available |
| 88998 | Fivid Tablet | Strip of 34 tablets | Not available |
All products are oral tablets.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score. There are no clinical trials or publications, and no plausible direct mechanistic link between a viral polymerase inhibitor and malignancy-associated HLH, which is driven by immune dysregulation. The infection-associated HLH prediction is a more reasonable research question, but it is also unsupported by any favipiravir data.
To proceed, the following is needed:
- Package insert warnings and contraindications from the India regulatory source (currently missing, and a blocker for safety screening)
- Detailed mechanism of action data (MOA)
- Any preclinical or clinical evidence of favipiravir in HLH, particularly the infection-associated form
- A mechanistic analysis comparing the original and new indications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.